Phase I trial of YHI-1003
Phase 1
- Conditions
- relapsed or refractory neuroblastoma
- Registration Number
- JPRN-jRCT2080222084
- Lead Sponsor
- Yakult Honsha Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
(1)Patients were previously diagnosed with neuroblastoma
(2)Patients must have relapsed or refracted against the standard therary
Exclusion Criteria
(1)Patients were previously treated with Perifosine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>CTCAE v.4.0
- Secondary Outcome Measures
Name Time Method efficacy and pharmacokinetic profile